TrumpRx expands to everyday medicines and generic price comparisons

On May 18, 2026, the Trump administration expanded TrumpRx.gov beyond the branded most-favored-nation (MFN) deals it launched with in February, adding everyday medicines and retail generic price comparisons to the government-run site ^[1][2]. TrumpRx.gov now describes itself as offering "hundreds of generics" ^[2].

The site launched on February 5, 2026, with drugs from five manufacturers that had signed MFN pricing deals: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer ^[1]. At launch, the White House said patients could see reductions on 40 of the most popular and expensive branded medicines ^[1]. Under MFN pricing, US prices are set in line with the lowest prices paid by other developed nations ^[1].

The site's FAQ treats the two kinds of listings as separate, with one question asking how prices of generic drugs shown on TrumpRx differ from the "Presidential deals" ^[2]. The homepage displays a running total of "$700,000,000+ Saved for Americans" and says the site lists "hundreds of generics" ^[2]. How many generic products are compared, which retail pharmacies supply those prices, and how often the comparisons update have not been reported ^[2].

What the branded GLP-1 listings show

The February 5 fact sheet said the monthly price of Ozempic would fall from $1,028 and injectable Wegovy from $1,349 to an average of $350 and as low as $199, depending on dosage strength ^[1]. The Wegovy pill was listed as falling from $1,349 to as low as $149 ^[1]. Zepbound was listed as falling from $1,088 to an average of $346 and as low as $299 ^[1]. The site currently shows Ozempic at $199 a month, the Wegovy pen at $199, the Wegovy pill at $149 and Zepbound at $299 ^[2]. The fact sheet and the site give slightly different starting prices for Zepbound, $1,088 ^[1] and $1,087 ^[2].

The same fact sheet listed other examples, including the fertility drug Gonal-F at as low as $168 per pen, Cetrotide falling from $316 to $22.50, Ovidrel from $251 to $84, the COPD inhaler Bevespi Aerosphere from $458 to $51, the asthma inhaler Airsupra from $504 to $201, the eczema ointment Eucrisa from $792 to $158, insulin lispro at as low as $25 a month, and Duavee from $202 to $30 ^[1]. Prices depend on dosage strength in each case ^[1].

Why it matters for patients

For people paying cash for a GLP-1, TrumpRx.gov is one place where posted monthly prices for Ozempic, Wegovy and Zepbound can be compared side by side ^[1][2]. The amounts shown vary by dose, so the lowest figure on a listing is not necessarily the one that applies to a given prescription ^[1]. The numbers are those posted by the government and the site; nothing in the source material says they have been independently verified ^[1][2].

The new generic listings are a different category from the branded deals, and the site's own FAQ separates them ^[2]. Whether insurance can be used for purchases through the site, and whether TrumpRx prices are available at a local pharmacy, are among the questions the site lists for patients ^[2]. All four GLP-1 products named in the government materials are brand-name medicines covered by MFN deals, and no generic version of them is mentioned in those materials ^[1][2]. Whether GLP-1 drugs are included in the new generic comparisons has not been reported.

What happens next

The February fact sheet said drugs from additional companies that signed MFN deals would be added to the site "in the coming months," and that 16 such deals had been announced since September 30, 2025 ^[1]. The site's FAQ asks whether more retail and mail-order pharmacy options will be added over time ^[2]. On January 15, 2026, the president called on Congress to pass "The Great Healthcare Plan," which would codify the MFN savings ^[1]. No date for further generic additions to the site has been reported.